Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148908 | 0.84 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2ITGB3ITGB1ITGAV | |
| SCHEMBL8552264 | 0.84 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2ITGB3ITGB1ITGAV | |
| SCHEMBL3709754 | 0.83 | L3MBTL1 (0.54) | ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL3709752 | 0.83 | L3MBTL1 (0.54) | ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL6078316 | 0.82 | USP30 (0.47) | ALDH1A1L3MBTL1KDM2B | |
| SCHEMBL5966186 | 0.80 | FKBP1A (0.57) | ALDH1A1L3MBTL1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL5966137 | 0.80 | FKBP1A (0.57) | ALDH1A1L3MBTL1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL5966141 | 0.80 | FKBP1A (0.57) | ALDH1A1L3MBTL1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL11156359 | 0.80 | ACE (0.53) | ACE | |
| SCHEMBL14407796 | 0.79 | FKBP1A (0.56) | ALDH1A1L3MBTL1SMN1; SMN2ITGB3ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | ALDH1A1 2954/4885L3MBTL1 1373/4885KDM4E 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.